Vaccine Partnering During The Forecast Period 2017 - 2020: Global Deal Trends, Players And Financials

Researchmoz added Most up-to-date research on "Vaccine Partnering During The Forecast Period 2017 - 2020: Global Deal Trends, Players And Financials" to its huge collection of research reports.

The Global Vaccine Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in vaccine and adjuvant partnering deals
• Deal terms analysis
• Partnering agreement structure
• Partnering contract documents
• Top deals by value
• Most active dealmakers
• Average deal terms for vaccines

This report contains a comprehensive listing of all vaccine partnering deals announced since January 2009, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.

The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=487855

One of the key highlights of the report is that over 800 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Executive Summary

 
Chapter 1 – Introduction
 
Chapter 2 – Trends in vaccine dealmaking
2.1. Introduction
2.2. Vaccine partnering over the years
2.3. Vaccine partnering by deal type
2.4. Vaccine partnering by industry sector
2.5. Vaccine partnering by stage of development
2.6. Vaccine partnering by disease type
2.7. Partnering by specific vaccine technology type
 
Chapter 3 – Average financial deal terms for vaccine partnering
3.1. Introduction
3.2. Disclosed financials terms for vaccine partnering
3.3 Vaccine partnering headline values
3.4 Vaccine upfront payments
3.5 Vaccine deals with milestone payments
3.6 Vaccine deals with royalty rates

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=487855

In-Depth Understanding And Access To The Liver Cancer Partnering Trends Between 2017 - 2021

Researchmoz added Most up-to-date research on "In-Depth Understanding And Access To The Liver Cancer Partnering Trends Between 2017 - 2021" to its huge collection of research reports.

The Liver Cancer Partnering 2010-2015 report provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in liver cancer partnering deals
• Top Liver cancer deals by value
• Deals listed by company A-Z, industry sector, stage of development, technology type

The Liver Cancer Partnering 2010-2015 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 35 links to online copies of actual liver cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=251055

The initial chapters of this report provide an orientation of liver cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Liver cancer technologies and products.

Report scope

Liver Cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to Liver cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

• Trends in Liver cancer dealmaking in the biopharma industry since 2010
• Access to summary headline, upfront, milestone and royalty data
• Access to over 35 livercancer deals and contract documents where available
• The leading Liver cancer deals by value since 2010

In Liver Cancer Partnering 2010-2015, the available deals are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Company A-Z
• Industry sector
• Stage of development at signing

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=251055

Key Trends In Non-Hodgkin Lymphoma Partnering Deals During The Forecast Period 2017 - 2020

Researchmoz added Most up-to-date research on "Key Trends In Non-Hodgkin Lymphoma Partnering Deals During The Forecast Period 2017 - 2020" to its huge collection of research reports.

The Non-Hodgkin Lymphoma Partnering 2010-2015 report provides understanding and access to the non-hodgkin lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in non-hodgkin lymphoma partnering deals

Top non-hodgkin lymphoma deals by value

Deals listed by company A-Z, industry sector, stage of development, technology type

The Non-Hodgkin Lymphoma Partnering 2010-2015 provides understanding and access to the non-hodgkin lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of non-hodgkin lymphoma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors non-hodgkin lymphoma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 35 links to online copies of actual non-hodgkin lymphoma deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=257046

The initial chapters of this report provide an orientation of non-hodgkin lymphoma partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of non-hodgkin lymphoma technologies and products.

Report scope

Non-Hodgkin Lymphoma Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to non-hodgkin lymphoma trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

• Trends in non-hodgkin lymphoma dealmaking in the biopharma industry since 2010
• Access to summary headline, upfront, milestone and royalty data
• Access to over 35 non-hodgkin lymphoma deals
• The leading non-hodgkin lymphoma deals by value since 2010

In Non-Hodgkin Lymphoma Partnering 2010-2015, the available deals are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Company A-Z
• Industry sector

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=257046

Detailed Analysis Of Bladder Cancer Partnering Deals For The Period 2017 - 2021

Researchmoz added Most up-to-date research on "Detailed Analysis Of Bladder Cancer Partnering Deals For The Period 2017 - 2021" to its huge collection of research reports.

The Bladder Cancer Partnering 2010-2015 report provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in bladder cancer partnering deals
• Top bladder cancer deals by value
• Deals listed by company A-Z, industry sector, stage of development, technology type

The Bladder Cancer Partnering 2010-2015 provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of bladder cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bladder cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 35 links to online copies of actual bladder cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=257604

The initial chapters of this report provide an orientation of bladder cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. 

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bladder cancer technologies and products.

Report scope

Bladder Cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to bladder cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

• Trends in bladder cancer dealmaking in the biopharma industry since 2010
• Access to summary headline, upfront, milestone and royalty data
• Access to over 35 bladder cancer deals
• The leading bladder cancer deals by value since 2010

In Bladder Cancer Partnering 2010-2015, the available deals are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Company A-Z
• Industry sector
• Stage of development at signing
• Deal component type
• Technology type

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=257604

Comprehensive Review Of Global Oncology Partnering 2017 - 2019: Deal Trends, Players And Financials

Researchmoz added Most up-to-date research on "Comprehensive Review Of Global Oncology Partnering 2017 - 2019: Deal Trends, Players And Financials" to its huge collection of research reports.

The Global Cancer Diagnostics Partnering 2010-2016 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the world's leading healthcare companies.

• Trends in cancer diagnostics partnering deals
• Disclosed headlines, upfronts, milestones and royalties by stage of development
• Cancer diagnostics partnering contract documents
• Top cancer diagnostics deals by value

This report provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,170 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announded by that company, as well as contract documents, where available.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=303188

Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

Report scope

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Diagnostics trends and structure of deals entered into by leading companies worldwide.

Cancer Diagnostics Partnering Terms and Agreements includes:

• Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2010
• Analysis of Cancer Diagnostics deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life Cancer Diagnostics deals

In Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,170 Cancer Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?

Global Cancer Diagnostics Partnering 2010-2016 report provides the reader with the following key benefits:

• In-depth understanding of Cancer Diagnostics deal trends since 2010
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies
• Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies
• Identify most active Cancer Diagnostics dealmakers since 2010

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=303188

Ophthalmics Partnering Terms & Agreements | ResearchMoz

Researchmoz added Most up-to-date research on "Ophthalmics Partnering Terms & Agreements | ResearchMoz" to its huge collection of research reports.

The Ophthalmics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter ophthalmics partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors ophthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest ophthalmics deals and contracts announced in the healthcare sectors.

The initial chapters of this report provide an orientation of ophthalmics dealmaking and business activities. 

Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in ophthalmics dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

                             

Chapter 3 provides a review of the leading ophthalmics deals since 2009 listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=170889

                                                                       

Chapters 4 and 5 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of ophthalmics deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Ophthalmics Partnering Terms and Agreements provides the reader with the following key benefits:

 

• In-depth understanding of ophthalmics deal trends since 2009
• Access ophthalmics deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between ophthalmics partner companies
• Comprehensive access to over 400 links to actual ophthalmics deals entered into by the world’s biopharma companies 

Report scope

 

Ophthalmics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to ophthalmics trends and structure of deals entered into by leading companies worldwide.

 

OphthalmicsPartnering Terms and Agreements includes:

• Trends in ophthalmics dealmaking in the biopharma industry since 2009
• Analysis of ophthalmics deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of ophthalmics deal contract documents
• Comprehensive access to over 400 ophthalmics deal records
• The leading ophthalmics deals by value since 2009
• Most active ophthalmics dealmakers since 2009

 

In Opthalmics Partnering Terms and Agreements, available deals and contracts are listed by:

• Headline value and opfront payment value
• Royalty rate value

Stage of development at signing

• Deal component type
• Technology type
• Specific therapy indication

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=170889